{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:52:16Z","timestamp":1789757536893,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS079568"],"award-info":[{"award-number":["R01NS079568"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS082536"],"award-info":[{"award-number":["R01NS082536"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009744","name":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13395-019-0197-y","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T15:02:22Z","timestamp":1558969342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A GDF11\/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-7024","authenticated-orcid":false,"given":"Quan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"197_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0925-4773(98)00205-6","volume":"80","author":"M Nakashima","year":"1999","unstructured":"Nakashima M, Toyono T, Akamine A, Joyner A. Expression of growth\/differentiation factor 11, a new member of the BMP\/TGF\u03b2 superfamily during mouse embryogenesis. Mech Dev. 1999;80:185\u20139.","journal-title":"Mech Dev"},{"key":"197_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/10320","volume":"22","author":"AC McPherron","year":"1999","unstructured":"McPherron AC, Lawler AM, Lee S-J. Regulation of anterior\/posterior patterning of the axial skeleton by growth\/differentiation factor 11. Nat Genet. 1999;22:260\u20134.","journal-title":"Nat Genet"},{"key":"197_CR3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1126\/science.1110175","volume":"308","author":"J Kim","year":"2005","unstructured":"Kim J, et al. GDF11 controls the timing of progenitor cell competence in developing retina. Science. 2005;308:1927\u201330.","journal-title":"Science"},{"key":"197_CR4","first-page":"6163","volume":"131","author":"EB Harmon","year":"2004","unstructured":"Harmon EB, et al. GDF11 modulates NGN3+ islet progenitor cell number and promotes beta-cell differentiation in pancreas development. Dev Camb Engl. 2004;131:6163\u201374.","journal-title":"Dev Camb Engl"},{"key":"197_CR5","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1101\/gad.1021802","volume":"16","author":"SP Oh","year":"2002","unstructured":"Oh SP, et al. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 2002;16:2749\u201354.","journal-title":"Genes Dev"},{"key":"197_CR6","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1242\/dev.02478","volume":"133","author":"J-P Liu","year":"2006","unstructured":"Liu J-P. The function of growth\/differentiation factor 11 (Gdf11) in rostrocaudal patterning of the developing spinal cord. Development. 2006;133:2865\u201374.","journal-title":"Development"},{"key":"197_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1210\/mend.13.1.0218","volume":"13","author":"J-J Lebrun","year":"1999","unstructured":"Lebrun J-J, Takabe K, Chen Y, Vale W. Roles of pathway-specific and inhibitory Smads in Activin receptor signaling. Mol Endocrinol. 1999;13:15\u201323.","journal-title":"Mol Endocrinol"},{"key":"197_CR8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.embor.7400752","volume":"7","author":"O Andersson","year":"2006","unstructured":"Andersson O, Reissmann E, Ib\u00e1\u00f1ez CF. Growth differentiation factor 11 signals through the transforming growth factor-\u03b2 receptor ALK5 to regionalize the anterior\u2013posterior axis. EMBO Rep. 2006;7:831\u20137.","journal-title":"EMBO Rep"},{"key":"197_CR9","doi-asserted-by":"publisher","first-page":"C1248","DOI":"10.1152\/ajpcell.00104.2009","volume":"296","author":"R Sartori","year":"2009","unstructured":"Sartori R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol. 2009;296:C1248\u201357.","journal-title":"Am J Physiol Cell Physiol"},{"key":"197_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2013.04.015","volume":"153","author":"FS Loffredo","year":"2013","unstructured":"Loffredo FS, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153:828\u201339.","journal-title":"Cell"},{"key":"197_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.1251141","volume":"344","author":"L Katsimpardi","year":"2014","unstructured":"Katsimpardi L, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344:630\u20134.","journal-title":"Science"},{"key":"197_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.1251152","volume":"344","author":"M Sinha","year":"2014","unstructured":"Sinha M, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344:649\u201352.","journal-title":"Science"},{"key":"197_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1161\/CIRCRESAHA.116.307962","volume":"118","author":"SC Harper","year":"2016","unstructured":"Harper SC, et al. Is growth differentiation factor 11 a realistic therapeutic for aging-dependent muscle defects? Circ Res. 2016;118:1143\u201350.","journal-title":"Circ Res"},{"key":"197_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.ymthe.2018.01.016","volume":"26","author":"Q Jin","year":"2018","unstructured":"Jin Q, Qiao C, Li J, Li J, Xiao X. Neonatal systemic AAV-mediated gene delivery of GDF11 inhibits skeletal muscle growth. Mol Ther. 2018;26:1109\u201317.","journal-title":"Mol Ther"},{"key":"197_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmet.2015.05.010","volume":"22","author":"MA Egerman","year":"2015","unstructured":"Egerman MA, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 2015;22:164\u201374.","journal-title":"Cell Metab"},{"key":"197_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.15252\/emmm.201607231","volume":"9","author":"DW Hammers","year":"2017","unstructured":"Hammers DW, et al. Supraphysiological levels of GDF11 induce striated muscle atrophy. EMBO Mol Med. 2017;9:531\u201344.","journal-title":"EMBO Mol Med"},{"key":"197_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00395-017-0639-9","volume":"112","author":"TA Zimmers","year":"2017","unstructured":"Zimmers TA, et al. Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. Basic Res Cardiol. 2017;112:48.","journal-title":"Basic Res Cardiol"},{"key":"197_CR18","doi-asserted-by":"crossref","unstructured":"Rinaldi F, Zhang Y, Mondragon-Gonzalez R, Harvey J, Perlingeiro RCR. Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice. Skelet Muscle. 2016;6(21).","DOI":"10.1186\/s13395-016-0092-8"},{"key":"197_CR19","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1073\/pnas.0709428105","volume":"105","author":"R Essalmani","year":"2008","unstructured":"Essalmani R, et al. In vivo functions of the proprotein convertase PC5\/6 during mouse development: Gdf11 is a likely substrate. Proc Natl Acad Sci U S A. 2008;105:5750\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"197_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/bdrc.20060","volume":"78","author":"G Ge","year":"2006","unstructured":"Ge G, Greenspan DS. Developmental roles of the BMP1\/TLD metalloproteinases. Birth Defects Res Part C Embryo Today Rev. 2006;78:47\u201368.","journal-title":"Birth Defects Res Part C Embryo Today Rev"},{"key":"197_CR21","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1128\/MCB.25.14.5846-5858.2005","volume":"25","author":"G Ge","year":"2005","unstructured":"Ge G, Hopkins DR, Ho W-B, Greenspan DS. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol. 2005;25:5846\u201358.","journal-title":"Mol Cell Biol"},{"key":"197_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. Biodrugs. 2017;31:317\u201334.","journal-title":"Biodrugs"},{"key":"197_CR23","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1128\/JVI.00649-08","volume":"82","author":"M Penaud-Budloo","year":"2008","unstructured":"Penaud-Budloo M, et al. Adeno-associated virus vector genomes persist as Episomal chromatin in primate muscle. J Virol. 2008;82:7875\u201385.","journal-title":"J Virol"},{"key":"197_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/humc.2017.010","volume":"28","author":"Y Sehara","year":"2017","unstructured":"Sehara Y, et al. Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson\u2019s disease. Hum Gene Ther Clin Dev. 2017;28:74\u20139.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"197_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994\u20132004.","journal-title":"N Engl J Med"},{"key":"197_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/mt.2008.283","volume":"17","author":"K Stieger","year":"2009","unstructured":"Stieger K, et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther. 2009;17:516\u201323.","journal-title":"Mol Ther"},{"key":"197_CR27","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","volume":"72","author":"X Xiao","year":"1998","unstructured":"Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224\u201332.","journal-title":"J Virol"},{"key":"197_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"197_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/bioinformatics\/btp184","volume":"25","author":"S Preibisch","year":"2009","unstructured":"Preibisch S, Saalfeld S, Tomancak P. Globally optimal stitching of tiled 3D microscopic image acquisitions. Bioinformatics. 2009;25:1463\u20135.","journal-title":"Bioinformatics"},{"key":"197_CR30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/clinchem\/22.5.650","volume":"22","author":"G Szasz","year":"1976","unstructured":"Szasz G, Gruber W, Bernt E. Creatine kinase in serum: 1. Determination of optimum reaction conditions. Clin Chem. 1976;22:650\u20136.","journal-title":"Clin Chem"},{"key":"197_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff E, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34:606\u201318.","journal-title":"Mol Cell Biol"},{"key":"197_CR32","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2012.144","volume":"20","author":"J Lovric","year":"2012","unstructured":"Lovric J, et al. Terminal differentiation of cardiac and skeletal myocytes induces Permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins. Mol Ther. 2012;20:2087\u201397.","journal-title":"Mol Ther"},{"key":"197_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.38","volume":"1","author":"AL Arnett","year":"2014","unstructured":"Arnett AL, et al. Adeno-associated viral vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev. 2014;1:14038.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"197_CR34","doi-asserted-by":"crossref","unstructured":"Schuster DJ, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 2014;8.","DOI":"10.3389\/fnana.2014.00042"},{"key":"197_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-61779-370-7_6","volume":"807","author":"MS Sands","year":"2011","unstructured":"Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol Clifton NJ. 2011;807:141\u201357.","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"197_CR36","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.0709144105","volume":"105","author":"AM Haidet","year":"2008","unstructured":"Haidet AM, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci. 2008;105:4318\u201322.","journal-title":"Proc Natl Acad Sci"},{"key":"197_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/hum.2007.159","volume":"19","author":"C Qiao","year":"2008","unstructured":"Qiao C, et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther. 2008;19:241\u201354.","journal-title":"Hum Gene Ther"},{"key":"197_CR38","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.2353\/ajpath.2010.090932","volume":"176","author":"KT Murphy","year":"2010","unstructured":"Murphy KT, et al. Antibody-directed Myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol. 2010;176:2425\u201334.","journal-title":"Am J Pathol"},{"key":"197_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/mus.21743","volume":"42","author":"KJ Morine","year":"2010","unstructured":"Morine KJ, et al. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve. 2010;42:722\u201330.","journal-title":"Muscle Nerve"},{"key":"197_CR40","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ajpath.2010.11.071","volume":"178","author":"EE Pistilli","year":"2011","unstructured":"Pistilli EE, et al. Targeting the Activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol. 2011;178:1287\u201397.","journal-title":"Am J Pathol"},{"key":"197_CR41","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1089\/hum.2011.102","volume":"22","author":"LT Bish","year":"2011","unstructured":"Bish LT, et al. Long-term systemic Myostatin inhibition via liver-targeted gene transfer in Golden retriever muscular dystrophy. Hum Gene Ther. 2011;22:1499\u2013509.","journal-title":"Hum Gene Ther"},{"key":"197_CR42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418\u201321.","journal-title":"Nature"},{"key":"197_CR43","first-page":"477","volume":"22","author":"M Nakatani","year":"2008","unstructured":"Nakatani M, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J Off Publ Fed Am Soc Exp Biol. 2008;22:477\u201387.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"197_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13395-018-0180-z","volume":"8","author":"A Iskenderian","year":"2018","unstructured":"Iskenderian A, et al. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone. Skelet Muscle. 2018;8:34.","journal-title":"Skelet Muscle"},{"key":"197_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"M St. Andre","year":"2017","unstructured":"St. Andre M, et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017;7:25.","journal-title":"Skelet Muscle"},{"key":"197_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2008.03.008","volume":"31","author":"MD Grounds","year":"2008","unstructured":"Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008;31:1\u201319.","journal-title":"Neurobiol Dis"},{"key":"197_CR47","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1126\/science.1071809","volume":"296","author":"L Attisano","year":"2002","unstructured":"Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science. 2002;296:1646\u20137.","journal-title":"Science"},{"key":"197_CR48","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tem.2014.06.002","volume":"25","author":"R Sartori","year":"2014","unstructured":"Sartori R, Gregorevic P, Sandri M. TGF\u03b2 and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends Endocrinol Metab TEM. 2014;25:464\u201371.","journal-title":"Trends Endocrinol Metab TEM"},{"issue":"11","key":"197_CR49","doi-asserted-by":"publisher","first-page":"e112268","DOI":"10.1371\/journal.pone.0112268","volume":"9","author":"Jenny A. Greig","year":"2014","unstructured":"Greig JA, et al. Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One. 2014;9.","journal-title":"PLoS ONE"},{"key":"197_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","volume":"13","author":"L Fagerberg","year":"2014","unstructured":"Fagerberg L, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics MCP. 2014;13:397\u2013406.","journal-title":"Mol Cell Proteomics MCP"},{"key":"197_CR51","doi-asserted-by":"publisher","first-page":"15842","DOI":"10.1073\/pnas.2534946100","volume":"100","author":"NM Wolfman","year":"2003","unstructured":"Wolfman NM, et al. Activation of latent myostatin by the BMP-1\/tolloid family of metalloproteinases. Proc Natl Acad Sci. 2003;100:15842\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"197_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/mus.20175","volume":"31","author":"S Girgenrath","year":"2005","unstructured":"Girgenrath S, Song K, Whittemore L-A. Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. Muscle Nerve. 2005;31:34\u201340.","journal-title":"Muscle Nerve"},{"key":"197_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MCO.0b013e328360272d","volume":"16","author":"Y Wang","year":"2013","unstructured":"Wang Y, Pessin JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2013;16:243\u201350.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"197_CR54","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/mt.2014.90","volume":"22","author":"K Relizani","year":"2014","unstructured":"Relizani K, et al. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. Mol Ther J Am Soc Gene Ther. 2014;22:1423\u201333.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"197_CR55","doi-asserted-by":"publisher","first-page":"19371","DOI":"10.1074\/jbc.M802585200","volume":"283","author":"ZB Li","year":"2008","unstructured":"Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem. 2008;283:19371\u20138.","journal-title":"J Biol Chem"},{"key":"197_CR56","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1242\/jcs.090365","volume":"125","author":"ZB Li","year":"2012","unstructured":"Li ZB, Zhang J, Wagner KR. Inhibition of myostatin reverses muscle fibrosis through apoptosis. J Cell Sci. 2012;125:3957\u201365.","journal-title":"J Cell Sci"},{"key":"197_CR57","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90:3710\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"197_CR58","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/BF00121296","volume":"14","author":"P Moens","year":"1993","unstructured":"Moens P, Baatsen PH, Mar\u00e9chal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil. 1993;14:446\u201351.","journal-title":"J Muscle Res Cell Motil"},{"key":"197_CR59","doi-asserted-by":"crossref","unstructured":"Kornegay JN, et al. Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. Skelet Muscle. 2016;6.","DOI":"10.1186\/s13395-016-0085-7"},{"key":"197_CR60","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","volume":"5","author":"KJ Nowak","year":"2004","unstructured":"Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5:872\u20136.","journal-title":"EMBO Rep"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-019-0197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13395-019-0197-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-019-0197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:14:40Z","timestamp":1590448480000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-019-0197-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1186\/s13395-019-0197-y","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"26 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal care and experimental protocols were approved by the University of North Carolina Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"16"}}